Company Overview

Cardio Diagnostics Holdings, Inc. is a publicly traded precision cardiovascular medicine company focused on the development and commercialization of epigenetic-based diagnostic tests. The company operates at the intersection of cardiovascular diagnostics, molecular biology, and preventive healthcare, with the objective of enabling earlier detection and risk stratification of coronary heart disease. Its primary offerings are blood-based clinical tests that analyze DNA methylation and genetic biomarkers associated with cardiovascular risk.

The company’s core revenue drivers are its proprietary diagnostic tests designed for clinical use, particularly Epi+Gen CHD® and PrecisionCHD™, which are positioned to complement or improve upon traditional cardiovascular risk assessment methods. Cardio Diagnostics primarily serves healthcare providers, clinical laboratories, and health systems seeking more precise tools for identifying patients at elevated risk of coronary heart disease. The company traces its origins to academic research and was formed to commercialize licensed intellectual property related to epigenetic biomarkers, later becoming a publicly listed entity through a merger with a special purpose acquisition company.

Business Operations

Cardio Diagnostics conducts its business through a single primary operating segment focused on cardiovascular diagnostic testing, encompassing research and development, clinical validation, regulatory compliance, and commercialization. The company generates revenue through the sale of laboratory-developed tests processed via certified clinical laboratories, with an emphasis on physician-ordered diagnostics. Operations include biomarker discovery, bioinformatics analysis, and the development of proprietary algorithms used in its tests.

The company’s operations are primarily based in the United States, with laboratory testing conducted through CLIA-certified partners and internal infrastructure. Cardio Diagnostics controls intellectual property licensed from academic institutions and maintains commercial relationships with laboratory service providers rather than operating large-scale in-house lab facilities. As of the latest public disclosures, the company does not report material joint ventures but relies on strategic collaborations with research institutions and clinical partners to support validation studies and market adoption.

Strategic Position & Investments

Strategically, Cardio Diagnostics positions itself as a differentiated player in preventive cardiology by leveraging epigenetic science, which it asserts provides actionable insights beyond conventional lipid panels and genetic-only tests. Growth initiatives focus on expanding clinical adoption, obtaining broader insurance reimbursement coverage, and generating additional clinical evidence to support guideline inclusion and physician confidence.

The company has invested significantly in research and development to expand its biomarker library and enhance its machine-learning–based risk assessment models. While Cardio Diagnostics has not announced large-scale acquisitions, it has made ongoing investments in intellectual property, clinical studies, and data infrastructure to support future test development. Emerging areas of focus include broader cardiometabolic risk assessment and potential expansion into adjacent cardiovascular conditions, subject to regulatory and clinical validation outcomes.

Geographic Footprint

Cardio Diagnostics is headquartered in the United States, with its principal executive offices located in Illinois. Its commercial activities are currently concentrated in the U.S. healthcare market, where regulatory pathways, reimbursement mechanisms, and clinical adoption efforts are focused. The company’s diagnostic tests are marketed to U.S.-based physicians and healthcare providers.

While international operations are limited, the company’s intellectual property portfolio and scientific research have global relevance, and management has indicated that future expansion outside the United States may be pursued as regulatory and commercial conditions permit. At present, there is no disclosed material revenue derived from non-U.S. markets.

Leadership & Governance

Cardio Diagnostics is led by a management team with backgrounds in healthcare, life sciences, and diagnostics commercialization. The leadership emphasizes scientific rigor, clinical validation, and long-term value creation through preventive healthcare innovation.

Key executives include:

• David J. Feldman – Chief Executive Officer
• Robert S. Philibert, MD, PhD – Chief Medical Officer
• Brandon Ballantyne – Chief Financial Officer
• Megha Singh, PhD – Chief Science Officer

The company operates under a board-governed structure consistent with U.S. public company standards, with oversight of strategy, risk management, and regulatory compliance. Management has articulated a strategic vision centered on transforming cardiovascular care through earlier, more precise diagnostic insights grounded in epigenetic science.